Skip header and navigation

Refine By

   MORE

17 records – page 1 of 2.

[Acute psychosis following bupropion overdosage]

https://arctichealth.org/en/permalink/ahliterature91227
Source
Ugeskr Laeger. 2008 Nov 10;170(46):3777-8
Publication Type
Article
Date
Nov-10-2008
Author
Hansen Maria Bergkvist
Rasmussen Kirsten Braendholt
Braendholt Vagn
Author Affiliation
Børneafdelingen, Sygehus Syd Naestved, DK-4700 Naestved. mihs@regionsjaelland.dk
Source
Ugeskr Laeger. 2008 Nov 10;170(46):3777-8
Date
Nov-10-2008
Language
Danish
Publication Type
Article
Keywords
Adolescent
Antidepressive Agents, Second-Generation - administration & dosage - poisoning
Bupropion - administration & dosage - poisoning
Hallucinations - chemically induced
Humans
Male
Overdose
Psychoses, Substance-Induced - etiology
Abstract
Bupropion is an antidepressant, which in Denmark is only used as an aid for smoking cessation. The toxicological side-effects include insomnia, gastrointestinal symptoms, tachycardia and seizures. A case of intentional overdose in a fourteen-year-old boy is presented. He developed hallucinations and tachycardia after ingesting only 1500 mg of bupropion, but recovered without sequelae.
PubMed ID
19014730 View in PubMed
Less detail

Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.

https://arctichealth.org/en/permalink/ahliterature171310
Source
Curr Med Res Opin. 2006 Jan;22(1):83-94
Publication Type
Article
Date
Jan-2006
Author
A A Tahami Monfared
D. Han
O. Sheehy
B. Bexton
J. Lelorier
Author Affiliation
Pharmacoepidemiology and Pharmacoeconomics Research Unit, Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Montreal, Quebec, Canada.
Source
Curr Med Res Opin. 2006 Jan;22(1):83-94
Date
Jan-2006
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antidepressive Agents, Second-Generation - administration & dosage - economics - therapeutic use
Canada
Cyclohexanols - administration & dosage - economics - therapeutic use
Depression - drug therapy - economics
Direct Service Costs
Female
Health Expenditures
Humans
Male
Middle Aged
Serotonin Uptake Inhibitors - economics - therapeutic use
Abstract
Empirical studies of antidepressant cost-effectiveness suggest that the use of venlafaxine may be no more costly than selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression. The objectives of this study were to identify patients' characteristics and factors associated with the choice of antidepressant and to assess differences in persistence, healthcare utilization and direct medical costs associated with venlafaxine and SSRIs pharmacotherapy.
We examined demographic and clinical characteristics of patients (n = 17 144) who received both a diagnosis of depression and a prescription for venlafaxine or an SSRI between 1996 and 2004 using the Quebec health administrative databases. Logistic regression models were used to identify factors independently associated with the choice of antidepressant. Persistence to treatment and overall direct medical costs during 12 months after initiation of therapy were assessed using Cox proportional hazard and GLM models, respectively.
Age, sex, provider specialty, and prior 12-month healthcare utilization significantly influenced initial antidepressant choice. Fewer venlafaxine-treated patients discontinued their initial therapy relative to SSRIs' (persistence to initial treatment: 38.4% vs. 29.4% and 24.4% vs. 15.8% at 6 and 12 months, respectively; p
PubMed ID
16393434 View in PubMed
Less detail

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.

https://arctichealth.org/en/permalink/ahliterature98055
Source
Acta Oncol. 2010 Apr;49(3):305-12
Publication Type
Article
Date
Apr-2010
Author
Timothy L Lash
Deirdre Cronin-Fenton
Thomas P Ahern
Carol L Rosenberg
Kathryn L Lunetta
Rebecca A Silliman
Stephen Hamilton-Dutoit
Jens Peter Garne
Marianne Ewertz
Henrik Toft Sørensen
Lars Pedersen
Author Affiliation
Department of Clinical Epidemiology, Aarhus University Hospital, Denmark. tl@dce.au.dk
Source
Acta Oncol. 2010 Apr;49(3):305-12
Date
Apr-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antidepressive Agents, Second-Generation - administration & dosage - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Breast Neoplasms - epidemiology - prevention & control
Citalopram - administration & dosage - adverse effects
Cytochrome P-450 CYP2D6 - antagonists & inhibitors
Denmark - epidemiology
Depression - drug therapy
Estrogen Receptor Modulators - therapeutic use
Female
Humans
Middle Aged
Neoplasm Recurrence, Local - epidemiology - prevention & control
Registries
Risk assessment
Risk factors
Serotonin Uptake Inhibitors - administration & dosage - adverse effects
Tamoxifen - therapeutic use
Abstract
BACKGROUND: Up to one-quarter of breast cancer patients suffer clinically significant depression in the year after diagnosis, which may respond to intervention. About half may be prescribed a psychotropic medication, such as a selective serotonin reuptake inhibitor (SSRI), while completing breast cancer therapy. Cytochrome P-450 2D6 (CYP2D6) metabolizes SSRIs and also metabolizes tamoxifen to more active forms. Therefore, concurrent use of SSRIs may reduce tamoxifen's effectiveness at preventing breast cancer recurrence. The SSRI citalopram has limited potency to inhibit CYP2D6 activity, so has been recommended for breast cancer patients taking tamoxifen. This study provides epidemiologic evidence to support this recommendation. MATERIAL AND METHODS: We conducted a case-control study of breast cancer recurrence nested in the population of female residents of Denmark who were diagnosed with non-metastatic estrogen-receptor positive breast cancers between 1994 and 2001 and who took tamoxifen for at least one year. We ascertained complete prescription histories by linking cases' and controls' civil registration numbers to the Danish national prescription registry. We estimated the association between SSRI use while taking tamoxifen and risk of recurrent breast cancer. RESULTS: About the same proportion of recurrent cases (37 of 366) and matched controls (35 of 366) received at least one prescription for citalopram or its s-stereoisomer while taking tamoxifen (adjusted odds ratio = 1.1, 95% confidence interval = 0.7, 1.7). Breast cancer patients taking other SSRIs were also at no increased risk of recurrence (adjusted odds ratio = 0.9, 95% confidence interval = 0.5, 1.8). DISCUSSION: Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen.
PubMed ID
20156115 View in PubMed
Less detail

The effects of becoming an entrepreneur on the use of psychotropics among entrepreneurs and their spouses.

https://arctichealth.org/en/permalink/ahliterature142422
Source
Scand J Public Health. 2010 Dec;38(8):857-63
Publication Type
Article
Date
Dec-2010
Author
Michael S Dahl
Jimmi Nielsen
Ramin Mojtabai
Author Affiliation
Department of Business Studies, Aalborg University, Fibigerstræde 4, Denmark. md@business.aau.dk
Source
Scand J Public Health. 2010 Dec;38(8):857-63
Date
Dec-2010
Language
English
Publication Type
Article
Keywords
Adult
Antidepressive Agents, Second-Generation - administration & dosage
Denmark
Drug Prescriptions - statistics & numerical data
Drug Utilization - statistics & numerical data
Entrepreneurship
Female
Humans
Hypnotics and Sedatives - administration & dosage
Male
Middle Aged
Psychotropic Drugs - administration & dosage
Registries
Serotonin Uptake Inhibitors - administration & dosage
Socioeconomic Factors
Spouses - psychology
Stress, Psychological - drug therapy - etiology
Workload
Abstract
Entering entrepreneurship (i.e. becoming an entrepreneur) is known to be a demanding activity with increased workload, financial uncertainty and increased levels of stress. However, there are no systematic studies on how entering entrepreneurship affects the people involved.
The authors investigated prescriptions of psychotropics for 6,221 first-time entrepreneurs from 2001-2004 and their 2,381 spouses in the first two years after becoming entrepreneurs in a matched case-control study using linked data from three Danish national registries: The Danish database for Labor Market Research, the Danish Entrepreneurship database and the Danish Prescription database.
Entrepreneurs were more likely to fill prescriptions at pharmacies for sedatives/hypnotics (adjusted odds ratio (AOR): 1.45 [95% CI: 1.26-1.66], p
PubMed ID
20601437 View in PubMed
Less detail

The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial.

https://arctichealth.org/en/permalink/ahliterature46208
Source
Addiction. 1999 Jul;94(7):1007-15
Publication Type
Article
Date
Jul-1999
Author
T. Blondal
L J Gudmundsson
K. Tomasson
D. Jonsdottir
H. Hilmarsdottir
F. Kristjansson
F. Nilsson
U S Bjornsdottir
Author Affiliation
Reykjavik Primary Health Care Centre, Iceland. Thorsteinn.Blondal@hr.is
Source
Addiction. 1999 Jul;94(7):1007-15
Date
Jul-1999
Language
English
Publication Type
Article
Keywords
Adult
Aged
Algorithms
Antidepressive Agents, Second-Generation - administration & dosage - blood
Double-Blind Method
Drug Therapy, Combination
Female
Fluoxetine - administration & dosage - blood
Humans
Male
Middle Aged
Nicotine - administration & dosage - blood
Nicotinic Agonists - administration & dosage - blood
Research Support, Non-U.S. Gov't
Respiratory Therapy
Smoking Cessation - methods
Abstract
AIMS: Nicotine replacement therapy (NRT) is an established aid in stopping smoking, while the role of antidepressants remains uncertain. Antidepressants added to NRT might improve abstinence rates. Our aim was to determine the efficacy of nicotine inhaler and fluoxetine vs. nicotine inhaler and placebo in attempts to quit smoking. DESIGN: A randomized, double-blind, placebo-controlled trial. SETTING: A smoker's cessation clinic. PARTICIPANTS: One hundred volunteers smoking 10 cigarettes/day or more. INTERVENTIONS: Subjects were instructed to start taking a daily dose of 10 mg of fluoxetine or placebo 16 days before stopping smoking, then 20 mg 10 days before quitting, continuing for up to at least 3 months. Subjects were instructed to use 6-12 units per day of nicotine inhalers after stopping smoking for up to 6 months. MEASUREMENTS: Continuous abstinence rates recorded at various time points up to 12 months from the quit date. FINDINGS: The sustained abstinence rate for the inhaler-fluoxetine group was 54%, 40%, 29% and 21% after 1.5, 3, 6 and 12 months, respectively, compared to 48%, 40%, 32% and 23% for the inhaler-placebo group. The differences were not significant at any time point. Abstinence up to 3 months was more likely in older smokers, those with a lower Beck Depression Inventory Score (BDI), lower Fagerström Test of Nicotine Dependence (FTND) score and no history of alcoholism. Fluoxetine appeared to increase abstinence rates among high BDI smokers compared to high BDI smokers assigned placebo. Serum levels of nicotine during treatment in the inhaler-fluoxetine group were lower than in the inhaler-placebo group so that fluoxetine may have reduced inhaler use through a common site of action. CONCLUSIONS: We found no evidence that fluoxetine treatment when used as an adjunct to NRT in unselected smokers is effective, but there may be an advantage to using it in depressed smokers.
PubMed ID
10707439 View in PubMed
Less detail

Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety.

https://arctichealth.org/en/permalink/ahliterature164029
Source
Vet Ther. 2007;8(1):18-31
Publication Type
Article
Date
2007
Author
Barbara Sherman Simpson
Gary M Landsberg
Ilana R Reisner
John J Ciribassi
Debra Horwitz
Katherine A Houpt
Tracy L Kroll
Andrew Luescher
Kelly S Moffat
Genefer Douglass
Carol Robertson-Plouch
Melissa F Veenhuizen
Alan Zimmerman
Terrence P Clark
Author Affiliation
Veterinary Behavior Clinic, Southern Pines, NC 28387, USA.
Source
Vet Ther. 2007;8(1):18-31
Date
2007
Language
English
Publication Type
Article
Keywords
Administration, Oral
Animals
Antidepressive Agents, Second-Generation - administration & dosage
Anxiety, Separation - drug therapy - psychology
Behavior, Animal
Bonding, Human-Pet
Canada
Dog Diseases - drug therapy - psychology
Dogs
Double-Blind Method
Fluoxetine - administration & dosage
Humans
Serotonin Uptake Inhibitors - administration & dosage
Treatment Outcome
United States
Abstract
Canine separation anxiety is a common behavioral problem presented to veterinarians. Associated behaviors are distressing to both dog and owner, have the potential to disrupt the human-companion animal bond, and may lead to euthanasia. The results of this study demonstrate the clinical efficacy and safety of Reconcile (fluoxetine, 1 to 2 mg/kg/day [0.45 to 0.91 mg/lb/day]), in conjunction with behavior management, for the treatment of canine separation anxiety. The beef flavored chewable formulation was palatable to treated dogs and easy to administer. This study provides to veterinarians and owners valuable information about an effective separation anxiety treatment plan that combines use of Reconcile with behavior modification.
PubMed ID
17447222 View in PubMed
Less detail
Source
Tidsskr Nor Laegeforen. 1999 Jun 10;119(15):2157-60
Publication Type
Article
Date
Jun-10-1999
Author
M. Thormodsen
P. Hjortdahl
T. Farbrot
O V Jacobsen
J B Nenningsland
B B Nielsen
Author Affiliation
Farsund apotek.
Source
Tidsskr Nor Laegeforen. 1999 Jun 10;119(15):2157-60
Date
Jun-10-1999
Language
Norwegian
Publication Type
Article
Keywords
Anti-Anxiety Agents - administration & dosage
Antidepressive Agents - administration & dosage
Antidepressive Agents, Second-Generation - administration & dosage
Benzodiazepines
Drug Prescriptions - statistics & numerical data
Drug Utilization
Humans
Norway
Physician's Practice Patterns
Registries
Serotonin Uptake Inhibitors - administration & dosage
Substance-Related Disorders - prevention & control
Abstract
The National Health Insurance started to refund expenditure on selective serotonin reuptake inhibitors in 1994. Questions have been raised if a significant portion of benzodiazepine users would transfer to these new drugs when they were described in the literature as also being used for light anxiety, but not carrying the addiction risk associated with benzodiazepines. The study looks at changes over a four-year period in the prescription of benzodiazepines and selective serotonin reuptake inhibitors dispensed from two pharmacies in Vest-Agder County with a total customer base of 17,800. For four years we also followed the prescription of drugs in these two groups to 1,125 patients who had been prescribed benzodiazepines in 1994. Our data show that only 5% of those receiving benzodiazepines in 1994, whom we were able to track, changed to a selective serotonin reuptake inhibitor-only therapy. 18% used a combination of the two groups of drugs and 77% continued to use benzodiazepines as before. The increase in the number of patients receiving selective serotonin reuptake inhibitors during the study period is far greater than the increase measured by number of daily doses. Selective serotonin reuptake inhibitors seem to have little influence on the use of benzodiazepines in our pharmacies' area. Our findings indicate that instead of "from Valium to Prozac" the change during the years 1994-97 can be described as "from Valium to Valium and Prozac".
Notes
Comment In: Tidsskr Nor Laegeforen. 1999 Jun 30;119(17):255910425913
PubMed ID
10402907 View in PubMed
Less detail

Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.

https://arctichealth.org/en/permalink/ahliterature195081
Source
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Feb;25(2):363-9
Publication Type
Article
Date
Feb-2001
Author
G. Remington
I. Khramov
Author Affiliation
Schizophrenia and Continuing Care Program, Clarke Division, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada.
Source
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Feb;25(2):363-9
Date
Feb-2001
Language
English
Publication Type
Article
Keywords
Administration, Oral
Adult
Antidepressive Agents, Second-Generation - administration & dosage - therapeutic use
Antipsychotic Agents - administration & dosage - therapeutic use
Clozapine - administration & dosage - therapeutic use
Delayed-Action Preparations
Emergency Service, Hospital - utilization
Female
Hospitalization - statistics & numerical data
Humans
Length of Stay - statistics & numerical data
Male
Middle Aged
Office visits - statistics & numerical data
Ontario
Patient Care - utilization
Patient compliance
Retrospective Studies
Risperidone - administration & dosage - therapeutic use
Schizophrenia - drug therapy
Schizophrenic Psychology
Abstract
1. Patients with schizophrenia who had been stabilized on their antipsychotic medication and subsequently maintained on it for a period of at least 18 months were identified: clozapine (N=15); risperidone (N=15); depot conventional (N=18); oral conventional (N=18). 2. Groups were compared on a clinical measure as well as the use of various health care services: hospitalizations; days in hospital, emergency room visits; physician and non-physician visits. 3. No differences between groups were found for hospitalizations, days in hospital, or emergency room visits, while physician and non-physician visits were highest in the clozapine group, in keeping with the need for routine hematologic monitoring in this population. The clozapine group had the highest baseline clinical scores and greatest number of previous hospitalizations. These treatment groups may reflect different clinical populations. However, the findings suggest that in drawing conclusions regarding long-term benefits of different agents, clinical or economic, it would prove useful to include in the evaluation a comparison of patients who have been stabilized on each of the treatments.
PubMed ID
11294482 View in PubMed
Less detail

[I give my patients a suicide weapon]

https://arctichealth.org/en/permalink/ahliterature68448
Source
Tidsskr Nor Laegeforen. 1997 Apr 10;117(9):1336-7
Publication Type
Article
Date
Apr-10-1997
Author
A. Egeland
Source
Tidsskr Nor Laegeforen. 1997 Apr 10;117(9):1336-7
Date
Apr-10-1997
Language
Norwegian
Publication Type
Article
Keywords
Antidepressive Agents, Second-Generation - administration & dosage - adverse effects
Humans
Norway
Physician's Practice Patterns
Prescriptions, Drug
Suicide, Assisted
Notes
Comment On: Tidsskr Nor Laegeforen. 1997 Mar 10;117(7):10039102994
PubMed ID
9182374 View in PubMed
Less detail

[New antidepressive agents--are they being used to much or too little?]

https://arctichealth.org/en/permalink/ahliterature46294
Source
Tidsskr Nor Laegeforen. 1998 Nov 30;118(29):4493
Publication Type
Article
Date
Nov-30-1998

17 records – page 1 of 2.